Analysis of Prazosin in Serum

Application

Clinical Research

Robert Ricker

Prazosin drug is designed as a blocker of alpha-adrenergic receptors. Blocking is selective for alpha-1 receptors and, therefore, reduces sympathetic activity to blood vessels without producing reflex tachycardia. Levels may be monitored to determine physiological levels in the blood stream upon treatment or misuse. On-line sample preparation/concentration using column switching enabled this analysis to be a fast, direct approach. The final analytical separation was performed using a ZORBAX SB-CN column. For details of the column switching technique visit the applications page of the ChromTech Website: **http://www.chromtech.se/biotrap**



Courtesy of ChromTech, Sweden

Conditions:
ZORBAX SB-CN, 4.6 x 150 mm, 5µm , Agilent P/N: 883975-905 + guard
Mobile phase: 35% ACN and 2 mM Na octanesulfonate in 116 mM Na phosphate, pH 2.8
F=1.0 mL/min, Det.: Fluorescence, ex = 340 nm, em = 385 nm

Highlights

- *After on-line extraction, prazosin in a 50 µL serum sample was analyzed using a ZORBAX SB-CN column.*
- *The analyte eluted from the ZORBAX SB-CN column with good peak shape.*
- *ZORBAX StableBond columns operate optimally and with excellent stability at low pH (e.g., 2.8).*

Agilent Technologies

Robert Ricker is an application chemist based at Agilent Technologies, Wilmington, Delaware.

For more information on our products and services, visit our website at:
www.agilent.com/chem

For Research Use only. Not for use in diagnostic procedures.

Information is subject to change without notice.

Printed in the USA
April 25, 2002
5988-6400EN

Agilent Technologies